NCT05349643View on ClinicalTrials.gov

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 26, 2023

Primary Completion Date

June 3, 2024

Study Completion Date

June 3, 2024

Conditions
Pigmented Villonodular SynovitisTGCTTenosynovial Giant Cell Tumor
Interventions
BIOLOGICAL

AMB-05X

A fully human monoclonal immunoglobulin (IgG2) directed against c-fms

Trial Locations (6)

33136

AmMax Bio, Clinical Site, Miami

77030

AmMax Bio, Clinical Site, Houston

95817

AmMax Bio, Clinical Site, Sacramento

Unknown

AmMax Bio, Clinical Site, Camperdown

AmMax Bio, Clinical Site, Woolloongabba

AmMax Bio, Clinical Site, Leiden

Sponsors

Lead Sponsor

AmMax Bio, Inc.
All Listed Sponsors
lead

AmMax Bio, Inc.

INDUSTRY

NCT05349643 - A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT | Biotech Hunter | Biotech Hunter